Laboratoire X.O begins a new stage of its growth with the support of Stanley Capital

,
04 October 2022, London – Stanley Capital Partners (SCP) has invested in a majority stake in French pharmaceutical group Laboratoire XO (Lab XO). Debt was provided by US lending giant Ares Management. Headquartered in Saint Cloud,…

New transaction for Laboratoire XO

,
Paris, October 29, 2021 - Laboratoire X.O has entered into a transaction with Astellas Pharma Inc. for the rights to nicardipine (3 brands) in 4 European countries. This will strengthen our portfolio of 24 brands and our European footprint. Since…

Laboratoire XO celebrates its 5th anniversary

,
Laboratoire X.O is a French success story. Our objective? To provide patients and healthcare professionals with innovative, qualitative products of real therapeutic interest. The story began in 2015 with the acquisition of 2 brands identified…

Laboratoire XO launches its brand new mouthwash

,
As part of the extension of Laboratoire X.O's range of OTC products, a new range of cosmetic mouthwashes with disruptive flavours has been launched: Prexifresh Mango & Mint. This is a daily treatment whose objective is to reduce the…

Signature of the laboratore X.O and VPS LIFEPHARMA

It was in the United Arab Emirates, and more precisely in Dubai at the opening of the Arab Health Meeting, that we signed a memorandum of understanding with a leading regional player, VPS LifePharma. VPS Healthcare's drug manufacturing arm,…

1 in 2 women suffer from painful periods…

,
1 femme sur 2 souffre de règles douloureuses... According to a study carried out on a representative sample of patients from the Social Security Health Examination Centres, 49% of non-menopausal women suffer from pain during their periods. Dysmenorrhoea…